

Louise Pitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7219340/publications.pdf>

Version: 2024-02-01

70
papers

4,124
citations

101543

36
h-index

114465

63
g-index

74
all docs

74
docs citations

74
times ranked

3562
citing authors

#	ARTICLE	IF	CITATIONS
1	Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. <i>Science Translational Medicine</i> , 2022, 14, eabi5229.	12.4	22
2	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the <i>Cynomolgus</i> Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	4.4	15
3	Eastern equine encephalitis virus rapidly infects and disseminates in the brain and spinal cord of cynomolgus macaques following aerosol challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010081.	3.0	9
4	Exposure Route Influences Disease Severity in the COVID-19 <i>Cynomolgus</i> Macaque Model. <i>Viruses</i> , 2022, 14, 1013.	3.3	10
5	The utilization of advance telemetry to investigate critical physiological parameters including electroencephalography in cynomolgus macaques following aerosol challenge with eastern equine encephalitis virus. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009424.	3.0	6
6	Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. <i>PLoS ONE</i> , 2021, 16, e0252874.	2.5	11
7	Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e231-e237.	9.1	42
8	Complete genomic sequences of Venezuelan equine encephalitis virus subtype IIID isolates from mosquitoes. <i>Archives of Virology</i> , 2020, 165, 1715-1717.	2.1	1
9	Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure. <i>PLoS Pathogens</i> , 2019, 15, e1008157.	4.7	21
10	Neutralizing Antibodies from Convalescent Chikungunya Virus Patients Can Cross-Neutralize Mayaro and Una Viruses. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1541-1544.	1.4	32
11	Virus-encoded miRNAs in Ebola virus disease. <i>Scientific Reports</i> , 2018, 8, 6480.	3.3	34
12	Countering Zika Virus: The USAMRIID Response. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1062, 303-318.	1.6	3
13	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S612-S626.	4.0	146
14	Qualitative Profiling of the Humoral Immune Response Elicited by rVSV- \hat{I}^{29} G-EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays. <i>Cell Reports</i> , 2018, 24, 1050-1059.e5.	6.4	11
15	African and Asian Zika Virus Isolates Display Phenotypic Differences Both In Vitro and In Vivo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 432-444.	1.4	65
16	Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 864-867.	1.4	18
17	Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. <i>Journal of Virology</i> , 2017, 91, .	3.4	34
18	Low potential for mechanical transmission of Ebola virus via house flies (<i>Musca domestica</i>). <i>Parasites and Vectors</i> , 2017, 10, 218.	2.5	8

#	ARTICLE	IF	CITATIONS
19	High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. <i>Emerging Infectious Diseases</i> , 2017, 23, 1274-1281.	4.3	74
20	Circulating microRNA profiles of Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 24496.	3.3	50
21	Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. <i>Viruses</i> , 2015, 7, 6739-6754.	3.3	29
22	Vaccines and Therapies for Biodefence Agents. <i>Journal of Immunology Research</i> , 2015, 2015, 1-2.	2.2	0

23

#	ARTICLE	IF	CITATIONS
37	Determination of Antibiotic Efficacy against <i>Bacillus anthracis</i> in a Mouse Aerosol Challenge Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1373-1379.	3.2	67
38	Pathology of Inhalational Anthrax Infection in the African Green Monkey. <i>Veterinary Pathology</i> , 2007, 44, 716-721.	1.7	41
39	Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. <i>Toxicon</i> , 2006, 47, 877-884.	1.6	41
40	Intranasal Protollinâ,ç/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. <i>Vaccine</i> , 2006, 24, 1625-1632.	3.8	50
41	A recombinant 63-kDa form of <i>Bacillus anthracis</i> protective antigen produced in the yeast <i>Saccharomyces cerevisiae</i> provides protection in rabbit and primate inhalational challenge models of anthrax infection. <i>Vaccine</i> , 2006, 24, 1501-1514.	3.8	21
42	Duration of protection of rabbits after vaccination with <i>Bacillus anthracis</i> recombinant protective antigen vaccine†. <i>Vaccine</i> , 2006, 24, 2530-2536.	3.8	49
43	Effects of Dexamethasone and Transient Malnutrition on Rabbits Infected with Aerosolized <i>Mycobacterium tuberculosis</i> CDC1551. <i>Infection and Immunity</i> , 2005, 73, 7056-7060.	2.2	14
44	Pathologic changes associated with brucellosis experimentally induced by aerosol exposure in rhesus macaques (<i>Macaca mulatta</i>). <i>American Journal of Veterinary Research</i> , 2004, 65, 644-652.	0.6	41
45	Susceptibility to Tuberculosis: Clues from Studies with Inbred and Outbred New Zealand White Rabbits. <i>Infection and Immunity</i> , 2004, 72, 1700-1705.	2.2	61
46	Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. <i>Vaccine</i> , 2004, 22, 422-430.	3.8	151
47	Pulmonary gene expression profiling of inhaled ricin. <i>Toxicon</i> , 2003, 41, 813-822.	1.6	44
48	Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule. <i>Vaccine</i> , 2003, 21, 2791-2796.	3.8	16
49	Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. <i>Clinical Immunology</i> , 2003, 108, 51-59.	3.2	70
50	Different Strains of <i>Mycobacterium tuberculosis</i> Cause Various Spectrums of Disease in the Rabbit Model of Tuberculosis. <i>Infection and Immunity</i> , 2003, 71, 6004-6011.	2.2	136
51	Impact of Inhalation Exposure Modality and Particle Size on the Respiratory Deposition of Ricin in BALB/c Mice. <i>Inhalation Toxicology</i> , 2003, 15, 619-638.	1.6	106
52	Impact of Inhalation Exposure Modality and Particle Size on the Respiratory Deposition of Ricin in BALB/c Mice. <i>Inhalation Toxicology</i> , 2003, 15, 619-638.	1.6	11
53	Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of <i>Yersinia pestis</i> in non-human primate and mouse models of pneumonic plague. <i>Vaccine</i> , 2002, 20, 2206-2214.	3.8	94
54	Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol. <i>Vaccine</i> , 2002, 20, 2623-2634.	3.8	49

#	ARTICLE	IF	CITATIONS
55	Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by <i>Bacillus anthracis</i> isolates of diverse geographical origin. <i>Vaccine</i> , 2001, 19, 3241-3247.	3.8	180
56	In vitro correlate of immunity in a rabbit model of inhalational anthrax. <i>Vaccine</i> , 2001, 19, 4768-4773.	3.8	250
57	Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. <i>Vaccine</i> , 1998, 16, 1056-1064.	3.8	57
58	Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. <i>Vaccine</i> , 1998, 16, 1141-1148.	3.8	208
59	Antibiotic Treatment of Experimental Pneumonic Plague in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 675-681.	3.2	96
60	Immediate responses of leukocytes, cytokines and glucocorticoid hormones in the blood circulation of monkeys following challenge with aerosolized staphylococcal enterotoxin B. <i>International Immunology</i> , 1997, 9, 1825-1836.	4.0	12
61	Comparative efficacy of a <i>Coxiella burnetii</i> chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. <i>Vaccine</i> , 1997, 15, 1779-1783.	3.8	36
62	Detection of Interleukin-6 and Interleukin-2 in Serum of Rhesus Monkeys Exposed to a Nonlethal Dose of Staphylococcal Enterotoxin B. <i>Military Medicine</i> , 1997, 162, 612-615.	0.8	17
63	Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure. <i>Toxicon</i> , 1996, 34, 1037-1044.	1.6	64
64	Lesions of Acute Inhaled Lethal Ricin Intoxication in Rhesus Monkeys. <i>Veterinary Pathology</i> , 1996, 33, 296-302.	1.7	108
65	Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. <i>Infection and Immunity</i> , 1996, 64, 4776-4787.	2.2	131
66	The distribution of [¹²⁵ I]ricin in mice following aerosol inhalation exposure. <i>Toxicology</i> , 1995, 98, 137-149.	4.2	38
67	Relationship Between Virulence and Immunity as Revealed in Recent Studies of the FI Capsule of <i>Yersinia pestis</i> . <i>Clinical Infectious Diseases</i> , 1995, 21, S178-S181.	5.8	139
68	Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol <i>Bacillus anthracis</i> spore challenge in guinea pigs. <i>Vaccine</i> , 1995, 13, 1779-1784.	3.8	92
69	Postexposure Prophylaxis against Experimental Inhalation Anthrax. <i>Journal of Infectious Diseases</i> , 1993, 167, 1239-1242.	4.0	389
70	Mucosal Priming Alters Pathogenesis of Rift Valley Fever. <i>Advances in Experimental Medicine and Biology</i> , 1988, 237, 717-723.	1.6	8